(RTTNews) - Novocure (NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer who have progressed on or after platinum-based chemotherapy. The MHLW approval was supported by the Phase 3 LUNAR trial.
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields or TTFields, which are delivered through non-invasive, wearable arrays.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
